{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:45:34Z","timestamp":1792025134641,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NCI Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Perioperative chemotherapy is the standard of care for resectable gastric cancer (GC), but many patients do not complete adjuvant chemotherapy (AC). It remains unclear whether AC following neoadjuvant chemotherapy (NAC) improves survival. We sought to assess differences in survival between patients with resectable GC who did vs did not receive AC after NAC and surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study was conducted at a tertiary cancer center to evaluate survival differences in patients who did vs did not receive AC. Patients with resected GC who received NAC were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 339 patients, 264 (78%) received AC. There were no significant differences in median event-free survival (EFS) (7.0 vs. 7.5\u2009years, P\u2009=\u2009.089) or overall survival (OS) (10 vs. 7.8\u2009years, P\u2009=\u2009.11) between AC and non-AC groups. In the node-negative (ypN\u2212) cohort (n\u2009=\u2009169), there was no association between AC receipt and EFS (12 vs. 10\u2009years, P\u2009=\u2009.7) or OS (12 vs. 10\u2009years, P\u2009=\u2009.5). In the node-positive (ypN+) cohort (n\u2009=\u2009170), AC receipt was associated with longer EFS (4.8 vs. 2.7\u2009years, P\u2009=\u2009.031) but not OS (5.5 vs. 2.8\u2009years, P\u2009=\u2009.071). High-risk patients based on lymph node ratio (LNR &amp;gt; 0.0685; n\u2009=\u2009112) who received AC (n\u2009=\u200987; 78%) had longer EFS (P\u2009=\u2009.014) and OS (P\u2009=\u2009.033). Finally, AC receipt was associated with longer EFS (P\u2009=\u2009.014) and OS (P\u2009=\u2009.024) in those with incomplete\/poor response to NAC (Becker tumor regression grade [TRG] 2-3).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>AC following NAC was not associated with improved survival in resected ypN- GC. High LNR identified a ypN\u2009+\u2009subgroup in which AC receipt was associated with longer EFS and OS. In patients with incomplete\/poor response to NAC (TRG 2-3), AC receipt was associated with longer EFS and OS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag384","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:42:34Z","timestamp":1790941354000},"source":"Crossref","is-referenced-by-count":0,"title":["Re-evaluating the role of adjuvant chemotherapy after neoadjuvant chemotherapy in resected gastric cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-2770","authenticated-orcid":false,"given":"Aravind","family":"Sreeram","sequence":"first","affiliation":[{"name":"Department of Surgery , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4663-4108","authenticated-orcid":false,"given":"Celine","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Medicine , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Toumbacaris","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela","family":"Capanu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoji","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Surgery , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Medicine , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yelena Y","family":"Janjigian","sequence":"additional","affiliation":[{"name":"Department of Medicine , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Ilson","sequence":"additional","affiliation":[{"name":"Department of Medicine , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian E","family":"Strong","sequence":"additional","affiliation":[{"name":"Department of Surgery , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-1038","authenticated-orcid":false,"given":"Geoffrey Y","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Medicine , Memorial Sloan Kettering Cancer Center , New York, NY 10065,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"2026101420021346500_oyag384-B1","doi-asserted-by":"publisher","first-page":"101404","DOI":"10.1016\/j.eclinm.2022.101404","article-title":"The current and future incidence and mortality of gastric cancer in 185 countries, 2020-40: a population-based modelling study","volume":"47","author":"Morgan","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2026101420021346500_oyag384-B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026101420021346500_oyag384-B3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"2026101420021346500_oyag384-B4","doi-asserted-by":"publisher","first-page":"e0189294","DOI":"10.1371\/journal.pone.0189294","article-title":"Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: a meta-analysis","volume":"13","author":"Li","year":"2018","journal-title":"PLoS One"},{"key":"2026101420021346500_oyag384-B5","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1200\/jco.2015.65.7692","article-title":"Effect of pathologic tumor response and nodal status on survival in the medical research council adjuvant gastric infusional chemotherapy trial","volume":"34","author":"Smyth","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026101420021346500_oyag384-B6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"2026101420021346500_oyag384-B7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026101420021346500_oyag384-B8","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"2026101420021346500_oyag384-B9","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1245\/s10434-020-09045-w","article-title":"Analysis of the survival impact of postoperative chemotherapy after preoperative chemotherapy and resection for gastric cancer","volume":"28","author":"Drake","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"2026101420021346500_oyag384-B10","doi-asserted-by":"publisher","first-page":"e225557","DOI":"10.1001\/jamanetworkopen.2022.5557","article-title":"Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy","volume":"5","author":"Lin","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2026101420021346500_oyag384-B11","doi-asserted-by":"publisher","first-page":"781742","DOI":"10.1155\/2013\/781742","article-title":"The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas","volume":"2013","author":"Mirza","year":"2013","journal-title":"Int J Surg Oncol"},{"key":"2026101420021346500_oyag384-B12","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1016\/j.ejso.2019.03.040","article-title":"Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival","volume":"45","author":"van Putten","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2026101420021346500_oyag384-B13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2026101420021346500_oyag384-B14","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/cncr.11660","article-title":"Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy","volume":"98","author":"Becker","year":"2003","journal-title":"Cancer"},{"key":"2026101420021346500_oyag384-B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","article-title":"Maximally selected rank statistics","volume":"48","author":"Lausen","year":"1992","journal-title":"Biometrics"},{"key":"2026101420021346500_oyag384-B16","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11&lt;2680::aid-cncr2820731105&gt;3.0.co;2-c","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"key":"2026101420021346500_oyag384-B17","doi-asserted-by":"publisher","first-page":"znaf056","DOI":"10.1093\/bjs\/znaf056","article-title":"Pathological response guides adjuvant 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy in surgically resected gastro-oesophageal cancer (SPACE-FLOT): international cohort study","volume":"112","author":"Investigators S-F","year":"2025","journal-title":"Br J Surg Mar"},{"key":"2026101420021346500_oyag384-B18","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0016-5085(99)70558-5","article-title":"Mismatch repair proficiency and in vitro response to 5-fluorouracil","volume":"117","author":"Carethers","year":"1999","journal-title":"Gastroenterology"},{"key":"2026101420021346500_oyag384-B19","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/1078-0432.Ccr-19-3728","article-title":"Mismatch Repair-Deficient rectal cancer and resistance to neoadjuvant chemotherapy","volume":"26","author":"Cercek","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026101420021346500_oyag384-B20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","article-title":"Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability\u2013high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study","volume":"41","author":"Andr\u00e9","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026101420021346500_oyag384-B21","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1200\/jco.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026101420021346500_oyag384-B22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1097\/sla.0000000000005320","article-title":"Distinct differences in gastroesophageal junction and gastric adenocarcinoma in 2194 patients: In Memory of Rebecca A. Carr, February 24, 1988-January 19, 2021","volume":"277","author":"Nakauchi","year":"2023","journal-title":"Ann Surg"},{"key":"2026101420021346500_oyag384-B23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","article-title":"Perioperative durvalumab in gastric and gastroesophageal junction cancer","volume":"393","author":"Janjigian","year":"2025","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag384\/71581739\/oyag384.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag384\/71581739\/oyag384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag384\/71581739\/oyag384.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:02:19Z","timestamp":1792022539000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag384\/8860754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag384","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,3]]},"article-number":"oyag384"}}